Table 1 Demographics and lesion characteristics of patients undergoing percutaneous transthoracic needle biopsy for persistent pulmonary consolidation
Characteristics | No (%) |
|---|---|
Age, yr. (mean ± SD) | 67 ± 10 |
Sex | |
Male | 17 (57) |
Female | 13 (43) |
Smoking history | |
Non-smoker | 8 (27) |
Current smoker | 4 (13) |
Former smoker | 18 (60) |
Bronchoscopy prior to PTNB | |
No | 23 (77) |
Yes | 7 (23) |
Underlying disease | |
None | 6 (20) |
Lung cancer | 15 (50) |
Other malignancy | 4 (13) |
Leukemia | 1 (3) |
Lymphoma | 1 (3) |
Pancreatic cancer | 1 (3) |
Breast cancer | 1 (3) |
Immunocompromised | 1 (3) |
Pulmonary disease | 4 (13) |
Indication for biopsy | |
R/O Infection | 9 (30) |
R/O Cancer | 9 (30) |
Molecular testing in known lung cancer | 12 (40) |
Treatment before biopsy | |
None | 23 (77) |
Antibiotic | 5 (17) |
Steroid | 1 (3) |
Antibiotic and Steroid | 1 (3) |
Chemotherapy and/or targeted therapy | 15 (50) |
Emphysema | |
Absent | 20 (67) |
Present | 10 (33) |
Lobar involvement of consolidation | |
< 1/2 Lobe | 10 (33) |
> 1/2 Lobe | 5 (17) |
> Lobe | 15 (50) |
Distribution | |
Single lung | 18 (60) |
Bilateral | 12 (40) |
Location of biopsied consolidation | |
Right upper lobe | 6 (20) |
Right middle lobe | 2 (7) |
Right lower lobe | 7 (23) |
Left upper lobe | 10 (33) |
Left lower lobe | 5 (17) |
Ground glass component | |
Absent | 10 (33) |
Present | 20 (67) |
Cavitation | |
Absent | 26 (87) |
Present | 4 (13) |
Hilar adenopathy | |
Absent | 21 (70) |
Present | 9 (30) |
Mediastinal adenopathy | |
Absent | 22 (73) |
Present | 8 (24) |
Pleural effusion | |
Absent | 17 (57) |
Present | 13 (43) |